Purpose/results/discussion. Rearrangem ent of the E W S gene with an ET S oncogene by chromosomal translocation is a hallmark of the Ewing family of tumors (EFT). Detectability, incidence, tumor speci® city and variability of this aberration have been m atters of intense investigation in recent years. A number of related alterations have also been found in other m alignancies. The common consequence of these gene rearrangements is the generation of an aberrant transcription factor. In EFT, the ETS partner is responsible for target recognition. However, synergistic and possibly tissue-restricted transcription factors interacting with either the EWS or the ETS portion m ay in¯uence target selection. M inimal domains of both fusion partners were de® ned that have proved necessary for the in vitro transformation of murine ® broblasts. These functional studies suggest a role for aberrant transcriptional regulation of transforming target genes by the chimeric transcription factors. Also, fusion of the two unrelated protein domains may affect overall protein conformation and consequently DNA binding speci® city. Recent evidence suggests that EWS, when fused to a transcription factor, interacts with differen t partners than germ -line EWS. Variability in EWS± ETS gene fusions has recently been demonstrated to correlate with clinical outcome. This ® nding may re¯ect functional differences of the individual chimeric transcription factors. Alternatively, type and availability of speci® c recom binases at different time-points of stem cell developm ent or in differen t stem cell lineages may determine fusion type. Studies on EFT cell lines using EWS± ETS antagonists do suggest a rate-limiting essential role for the gene rearrangement in the self-renewal capacity of EFT cells. The presence of additional aberrations varying in number and type that may account for immortalization and full transform ation is postulated. Knowledge about such secondary alterations may provide valuable prognostic m arkers that could be used for treatment strati® cation.
Introduction
Ew ing' s sarcom a (ES), being a rare m alignant disease affe cting bone and soft tissue in children and young adults, was hardly known to people other than pediatric oncologists until the characterization of a chim eric gene product presum ed to be causally involved in the generation of this neoplasm . It dram atically gained attention w hen, from investigating other m alignancies, it becam e apparent that the ES-derived oncoprotein constitutes the prototype of a whole class of aberrant proteins speci® cally asso ciated with certain tum or types. C onsequently, ES m ay be considered a m odel system to study m alignant conversion on a subclinical level. T he discovery of the ES-asso ciated gene rearrangement transiently halted a controversy among pathologists about the existence of distinct categories of ES (i.e. osseous ES, extra-sk eletal ES, Askin tum or, peripheral prim itive neuroectoderm al tum or) because it was found to be expressed in all of them . Clinically, however, there is a need for diversi® cation.
Although m ore than half of the patients can be cured by m ultimodal therapy, one third of cases with localized disease and about 80% of patients presenting with m etastases succum b to the disease (for a recent review, see K ovar et al. 1 ). Current treatment protocols have largely com pensated for classical prognostic m arkers such as tumor volum e and localization of the prim ary except for the rather unfavo rable presence of metastases at diagnosis. It is likely, therefore, that biological differences exist between so far incurable aggressive disease and clinically m anageable localized disease inexplicable by the m ere presence of the ES-assoc iated gene rearrangement. W hile Ewing' s tum or research has focused on the clinical exploitability and the function of the ES-spe ci® c gene rearrangem ent since its discovery in 1992, this review will also consider extensively the role of additional m olecular aberrations in the search for useful prognostic m arkers. N eoplastic transform ation and m etastatic spread is com m only believed to result from a m ulti-step pro-
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cess. In this context, the ES-spe ci® c gene rearrangement obviously constitutes a rate-lim iting event. According to Knudson' s legendary tw o-hit hypothesis, at least one additional aberration should be present in a Ewing tum or. It is possible that this second hit is less speci® c and affects different genes at different times during developm ent of the enigmatic Ewing tumor stem cell, thus de® ning distinct subcategories of the disease. C onsequently, Ew ing tum or research is slowly m oving towards m olecular subclassi® cation and staging.
D iagnostic tools
In 1988, the cytogenetic translocation t(11;22) (q24;q12) was described as speci® cally asso ciated w ith histopathologically diagnosed ES and peripheral prim itive neuroectoderm al tum or (pPN ET). 2 T he presence of this aberration in a largely undifferentiated small round cell tum or of childhood turned out to be a form idable diagnostic m arker. 3, 4 H ow ever, cytogenetic analysis was restricted to tum or cells with at least lim ited in vitro proliferation potential. T he generation of an antibody, H BA71, 5 speci® cally reacting with the surface glycoprotein encoded by the M IC2 gene, 6 which w as found to be abundantly present in tum or cells carrying a chrom osom e 22q12 aberration, 7, 8 enlarged the spectrum of diagnostic tools. H owever, em bryonal rhabdomyosarcom as, asterocytom as, neuroendocrine tum ors and carcinom as occasionally stained positive with HBA71 9 and, w hen using a m ore sensitive antibody (12E7 10 ), high level expression of this antigen was also noted in early hem atopoietic precursor cells 11 and several lymphom as. 12 The characterization of the ES break-po int regions on chrom osom es 22 and 11 13 and the subsequent cloning of a chim eric cD N A resulting from a gene fusion between a novel gene, designated E W S, and the E TS transcription factor gene FLI1 14 allowed for sensitive detection of tum or cells carrying a 11;22 translocation even in sm all sam ples of fresh, frozen or paraf® nem bedded m aterial by m eans of reverse transcriptase polym erase chain reaction (RT -PC R).
15± 18
Subsequently, several alternative fusion partners for E W S from the ETS oncogene fam ily were identi® ed in ES and pPN ET cases 19± 24 U sing the RT -PC R method, combined with genom ic analysis of the EW S break-point region, on a large series cf osseous and extra-ske letal ES (including Askin tum ors and pP N ET, designated Ewing fam ily of tum ors (EFT )) as opposed to several unrelated sm all round cell tum ors, the speci® city of the E W S± ETS gene rearrangement and the correlation w ith high M IC2 expression w as con® rm ed.
16± 25
Recently, however, the lim itation of this aberration to typical EF T m em bers has been questioned since Alternatively, antibodies to unique dom ains of the chim eric gene product could allow the routine pathologist to screen for the EW S rearran gem ent by standard im m unohistochem ical m ethods. T he author and others 125, 12 6 have recently obtained prelim inary indirect evidence from protein interaction studies that an am ino terminal E W S dom ain, w hich appears to be inaccessible in germ -line E W S, m ight be speci® cally exposed on the surface of the chim eric product (see below). O ne could endeavor, therefore, to generate an agent that distinctly recognizes the altered conform ation of the E W S portion present in EW S fusion proteins. T he hinge region of E W S± E T S chim eric proteins displays a high d egree of variab ility du e to variable break-p oint locations in the genes contributing to the translocation. So far, ® ve altern ative ETS family m em bers have been found in E W S gene rearrangem ents. T herefore, antibodies to the lin ker dom ain of fused partners would be of only lim ited use in routine diagnosis. For the an alysis of RT -PC R negative`atypical' E FT and for sm all round cell tum ors with a diagnosis other than EF T but RT -PC R positive for an EW S chim eric transcript, it is strongly recom m ended to con® rm the m olecular diagnosis by the dem onstration of an EW S aberration on either D N A level (FISH or Southern blot) or on RN A level by N orthern blotting. Presently, it cannot be excluded that using these approaches, follow ed by re® ned cloning procedures, fu rther E TS fam ily m em bers will be identi® ed as alternative fusion partners for E W S in E FT or non-E FT . 57 T his region was found to be reduced by 50% due to deletion in the African population. This inter-ethnic polymorphism in the EW S gene is accom panied by a striking difference in the incidence of EF T between populations of European and African origin. 58, 59 It should be noted that the m ajority of EW S genomic breakpoints occur in intron 7 and that intron 6 is, in fact, never directly rearranged in EF T. So far, only three E W S genom ic break-po ints have been sequenced, two in EF T and one in a desm oplastic sm all round cell tum or, 60± 62 , none of which contained Alu elem ents in the im mediate vicinity of the rearrangem ent sites. T hus, direct proof for the involvem ent of Alu elements in E W S translocation is not availab le.
In the published cases, the lack of uniform ity of sequences affe cted by the gene rearrangem ent does not allow the identi® cation of a speci® c recom binase responsible for the translocation. Chromosom e 22 alteration m ay occur as the only cytogenetically visible aberration in EF T suggesting that the EW S± E TS gene rearrangem ent is not the consequence of a general genomic destabilization. However, the frequent involvem ent of m ore than two chrom osom es in complex chrom osom e 22 aberrations and evidence for deletion of considerable am ounts of sequences from the directly involved genes on the untranscribed counterpart of the derivative chrom osom e 22 60 im ply a complex m echanism for gene rearrangement in EFT. In addition, w hile EW S and FLI1 are equally oriented on the long arm s of chrom osom es 22 and 11 from the centrom ere to the telom ere allow ing for sim ple reciprocal translocation, the E RG gene is oriented in the opposite direction. Consequently, EW S± ERG gene fusions m ay result from either interstitial deletion/insertion m echanism s 63 or from com plex genom ic rearrangem ents involving additional chrom osom es.
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Although a high variability in EW S fusion partners and genom ic break-point locations has been noted, rearrangement of EW S intron 7 w ith intron 5 or 4 of the ETS fam ily gene FLI1 predom inates (about 80% of EF T cases). 16, 18, 24 Interestingly, the only known three cases of fusion between EW S and the ETS transcription factor gene FE V involve E W S intron 10 which is otherw ise affe cted in only 9% of EFT . Since, as outlined later, the m inim al portions of EW S and its fusion partners contained in all EFT -derived oncoproteins and required for full in vitro transfo rm ation and transcription activation function are signi® cantly sm aller than the portions present in the m ost frequently observed EW S fusions, it is unlikely that in EFT rearrangement sites are determined by functional constraints only. Rather, genom ic structure and accessibility m ight direct illegitimate recom bination to speci® c regions in the involved genes. G enom ic accessibility and availability of recom binases m ight vary during the developm ent of speci® c stem cell lineages. Therefore, it cannot be excluded that the different E W S rearrangements de® ne different histogenetic starting points of EF T developm ent. This m odel would provide an intriguing explanation for our recent observation of prognostic differences in EFT correlating with different EW S fusion types. 18 Alternatively, the various chim eric oncoproteins m ight display functional differences. Since the com plete EW S and FLI1 genes have been cloned and sequence inform ation is readily availab le, 64± 65 the description of m ore genom ic rearrangement points in EFT will hopefully throw m ore light on the m echanism of gene rearrangem ent in this disease.
The ETS partner in the E W S fusion gene
T he ET S transcription factor fam ily currently counts m ore than 30 mem bers. It is characterized by the presence of a unique D N A binding domain which is highly conserved from¯ies to hum ans and has been ® rst described for the viral oncogene v-ets of avian erythroblastosis virus E 26 (E twentysix speci® c ET S1, G ABPa , and F LI1 have recently been demonstrated to bind to the transcription factor PAX 5 in vitro. 78 A¯anking PAX5 binding site allowed for ET S1 binding to an im perfect ET S recognition m otif indicating that cooperativity m ight change ET S binding speci® city to som e extent. Som e ET S proteins, including ETS1, ETS2, F LI1, ERG , G ABPa and TEL, share a further conserved region¯anking the am ino terminal transactivation dom ain, refered to as the`pointed or B-dom ain' . T his structure has been show n to de® ne a speci® c oligom erization interface. For T EL, it governs hom otypic aggregation. 79 N o interaction partner has been de® ned for FLI1 and ERG so far. 82 and antisense RN A to E1AF was able to revert it in a squam ous cell carcinom a cell line. 83 Strom elysin has also been demonstrated to be activated by ETS2, a m ember of another ET S subfam ily. 84 However, coexpression of ERG, w hich also strongly binds to the same prom oter but is by itself unable to activate it, resulted in inhibition of ET S2-m ediated strom elysin gene activation. 85 EL K is one of several alternative ternary com plex factors regulating a num ber of growth factor inducible genes. 87 In fact, EW S± F LI1 can replace EL K within the ternary com plex form ed on the serum response elem ent of the cfos and the EGR1 promoters. 88, 89 In contrast to germ -line FLI1, binding of EW S± FLI1 to the serum response element did not require interaction with the serum response factor SRF. T ernary com plex form ation by FLI1 and EW S± FLI1 was m ediated by a dom ain preceding the D N A binding dom ain and present in the m ajority of EFT -derived EW S± FLI1 fusions that show lim ited sim ilarity to the ELK1± SRF interaction dom ain. H ow ever, no hom ologous structure can be identi® ed in ERG and evidence for EW S± ERG involvem ent in ternary com plex form ation is not available.
In sum m ary, current know ledge about norm al and aberrant ET S proteins suggest a num ber of interesting candidate target genes for the EF Tspeci® c chim eric transcription factors, potentially involved in the regulation of cell growth, signaling and m etastasis, as revealed by the study of heterologous cellular system s such as m urine ® broblasts. H owever, am ple evidence exists that ET S transcription factor action is largely context speci® c. F or EFT , the cell of origin rem ains a m atter of speculation. Because of lim ited neural differentiation potential, EFT is considered as derived from the neuroectoderm . 90 Interestingly, X enopus FLI1 has been shown to be expressed in a restrictive pattern during embryogenesis evocative of neural crest cell invasio n. 66 It is therefore speculated that the activation of this transcription factor m ay be affe cting the self-renewal potential of the infected erythroid progenitors. However, leukem ogenesis proceeds in m ultiple steps and additional aberrations affe cting viab ility of cells (e.g. inactivation of the tum or suppressor gene p53) can be observed in F -M uLV induced erythroleukem ia. 91, 92 In contrast to ERG , 93 norm al FLI1 was reported to be unable to transfo rm m urine ® broblasts (NIH3T 3) while expression of an EW S fusion protein resulted in pronounced anchorage-independent clonogenicity of N IH 3T3 cells. 94, 95 H owever, rat embryo ® broblasts and som e m urine ® broblast subclones w ere resistant to EW S± FLI1-mediated transformation. These ® ndings again suggest that the oncogenic potential of norm al and aberrant FLI/ERG ET S subfam ily m embers m ay depend on a cell type-sp eci® c availability of relevant synergistic factors and possib ly on the presence of additional aberrations. N IH3T 3 transfection studies with various recom binant EW S± F LI1 deletion m utants revealed a dependence of transfo rm ation on both the EW S portion and the ETS dom ain. 95 However, optim al transactivation potential m ediated by the 30 EW S am ino term inal degenerate repeats included in almost all EFT -derived fusion proteins was dispensable for m axim al focus form ation of transfected N IH3T 3 in soft agar. T he m inim al EW S dom ain required to transform m urine ® broblasts was delineated to the ® rst 82 am ino acids. 94 Recently, evidence obtained shows that w ithin the EW S± FLI1 fusion protein, but not within germ -line EW S, this peptide directly contacts a com ponent of the RN A polym erase II complex, RP B7, and that this interaction is suf® cient to drive EW S± FLI1-m ediated reporter gene transactivation. 125 Interactions of fulllength EW S with the general transcription factor T FIID , an essential com ponent of the transcriptional preinitiation com plex, w ere absent from EW S fusion proteins. 126 It is therefore possible that fusion of the EW S amino terminus to the FLI1 D N A binding dom ain alters the protein conform ation and directly recruits RN A polym erase II to F LI1 target genes. Since RPB7 displays sim ilarities to prokaryotic sigm a factors, it m ight be involved in EFTspeci® c target site selection. T aken together, the EW S± ETS gene rearrangement appears to be involved in the aberrant self-renewal capacity of E FT cells but m ight not be suf® cient to guarantee survival of initiated tum or cells. However, as demonstrated recently, there m ight still be som e role for F LI1, ERG and their E W S fusions to play in the protection from stress (i.e. calcium ionophore and serum deprivation)-induced cell death.
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The second hit Assum ing that the EW S± ETS gene rearrangement is able to initiate EFT pathogenesis but is not suf® cient to generate m alignant transfo rm ation, the presence of additional m utations m ust be postulated. These aberrations m ight not necessarily be tum or speci® c but m ay display inter-individual variation that could account for variations in EF T phenotype as w ell as in clinical behavio r. Also, they m ay determ ine differentiation capacity, invasive potential and treatm ent resistance. Consequently, while from a clinical point of view the EW S± ETS gene rearrangement provides a valuable diagnostic tumor m arker, knowledge about the nature of additional aberrations in EFT m ay assist subclassi® cation and provide prognostic tools. Since studies on facultative genetic anomalies in EF T have been largely neglected since the discovery of the E W S± ETS gene rearrangements, enhanced efforts to de® ne the m ultitude of additional aberrations are warranted for the bene® t of patients.
C lues from cytogenetics
In three independent reviews of cytogenetically inform ative EF T cases, non-random num erical and structural chrom osom al aberrations were reported to occur with variable frequencies in addition to the tum or speci® c t(11;22)(q24;q12) 106± 107 (H attinger et al., unpublish ed). T hese include trisom y 8 in about 50% of cases frequently coupled with trisom y 12 occurring in roughly 20% , and a derivative chrom osom e 16 as a result of an unbalanced t(1;16) in 18% of EF T. In rarer cases, other aneuploidies have been identi® ed. Structural chrom osom e 1 aberrations that either result in gains of chrom osom e 1q21± 22 or relative losses of the short arm of chrom osom e 1, a frequent alteration in neuroblastom a and other neuroectoderm al tum ors, have also been observed in EFT (Hattinger et al., unpublished) . Interestingly, this chrom osomal region harbours a gene encoding a protein (p73) that is structurally and functionally related to the tum or suppressor p53, a transcription factor involved in the regulation of cell growth and apoptosis, and frequently inactivated during the progression of m any tum ors. 108, 109 W hile research currently focuses on the role of p73 for neuroblastom a pathogenesis, its relevance for a subset of EFT is som ething that has to be explored.
In general, excluding chrom osom e 22q12 translocations, num erical chrom osome changes are the m ost frequent cytogenetic ® ndings in EF T. T hese are likely to affect gene dosage. However, no candidate genes that could prom ote EW S± ETS-initiated EF T pathogenesis when expressed at aberrant levels have been identi® ed so far. Also, inform ation on genes affe cted by the recurrent chrom osom e 16 and 1 structural alterations is not available yet. Frequently, these cytogenetic alterations occur in only a subpopulation of neoplastic cells within the tum or suggesting that they m ay be associated with late stages of tumor progression.
The role of non-speci® c cancer genes
In the absence of recurrent candidate progressionasso ciated genetic alterations identi® able in EFT by the means of cytogenetics, work has focused on the analysis of m utations generally associated w ith a broad range of hum an m alignancies. Genes investigated during the last years include the oncogenes ras, cmyc and M DM 2, the tumor suppressors p53, p16, and Rb, the metatasis-asso ciated splice varian ts of the CD 44 adhesion m olecule, and the tum or-speci® c m etastasis suppressor gene nm 23H1. 110± 113,127 N one of the studied oncogenes w as found to be altered by m utation or in expression although occasional low level am pli® cation of M DM 2 has been reported in an independent study on a sim ilar sized cohort of EFT patients. 111 N either m utation nor differences in expression levels of the nucleotide diphosph ate-kinase nm 23H1 were observed irrespective of the disease extension. 112 O nly standard C D44 expression was detectable in EF T. 127 In contrast, hom ozygous deletions of the p16 tum or suppressor was identi® ed in about onethird of prim ary EFT sam ples. This ® nding was surprising since chrom osom al aberrations of band 9q21 containing the p16 gene were not reported before suggesting a high-freq uency of m icrodeletions. Expression studies on EFT cell lines suggested that the frequency of p16 inactivation m ight be even higher since post-transcriptional gene silencing w as observed in several cases. 113 p16 acts as an inhibitor of the cyclin D 1/cyclin-dependent kinase 4 (CD K 4) com plex that inactivates the cell cycle inhibitor pRb by phosph orylation. Inactivation of p16 should com prom ise the G1 cell cycle checkpoint. Over-expression of either cyclin D 1 or C D K4, or loss of pRb function, is believed to m ediate a sim ilar effect. 114 In fact, we observed frequent cyclin D 1 over-expression as well as variable CD K4 abundancy in EFT cell lines and loss of Rb in one case. How ever, expression data from prim ary tumor m aterial are not available yet. In addition, low level C DK4 am pli® cation w as previously reported for two of 30 EFT sam ples.
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In virally induced m alignancy, G1 check-point control is frequently com promised by concom ittant inactivation of the pRb and p53 pathways. In addition, F-M uLV-induced erythroleukem ia involves not only the activation of the FLI1 oncogene as a rate-lim iting step but also m utation of p53. T he author and others have, therefore, investigated the status and expression of p53 and related genes in EFT . 110, 115 T he frequency of p53 m utations in prim ary tumors w as found to be low er than 10% as opposed to a m ean frequency of 40± 60% in m ost hum an m alignancies. In contrast, in about half of EFT cell lines, the p53 gene was mutated and show ed loss of heterozygosity. Com pariso n of p53 gene status between cell lines and the respective prim ary tum ors of origin, w hen available, demonstrated that the observed increase in m utation frequency was due to selection and was not acquired during in vitro expansion of tumor cells. T his result suggested that p53 m utation m ight release EFT cells from som e in vivo grow th or survival factor dependency. Transient transfection and over-expression of wildtype p53 in cell lines with endogenous m utant or wildtype gene status demonstrated frequent but variable reduction in apoptotic responsiveness, 116 suggesting the presence of som e as yet unidenti® ed cell-protective m echanism in EF T cell lines. Preliminary expression analysis of m embers of the cell death regulatory Bcl2 gene fam ily did not reveal any signi® cant variations between individual EFT cell lines (our unpublished observations). Previously, high levels and activity of poly(AD P-rib ose) polym erase, a nuclear enzym e that participates in DN A replication, repair and the triggering of apoptosis induced by D N A strand breaks, have been reported for som e EFT cell lines. 117 Sensitivity of EFT cell lines to D N A dam aging agents (etoposide, actinom ycin D , X-rays) varied considerably in a m anner independent from p53 responsiveness and endogenous p53 gene status suggesting that com plete m utational or partial inhibition of the p53 apoptosis pathway in EFT cell lines plays a role different from radio-and chemosensitivity. However, the physiolo gical signals that stim ulate p53-dependent cell death have not been de® ned so far.
M olecular markers of prognosis
As a result of variable break-po int localization in the involved genes, EW S± ETS gene products vary considerably in size. M ost fusions include EW S exons 1 to 7 (89% ) and FLI1 exons 6 to 9 (54% ). E W S/FLI1 exon 7/6 fusions (type 1) predominate independent of the disease extension (51% ). In about one-third of EFT , FLI1 exon 5 is included into the chim eric gene product, m ost frequently joined to EW S exon 7 (type 2) (27%). In rare cases, the chrom osom al translocation results in the inclusion of EW S exons 9 (1%) or 9 plus 10 (10% ) or FLI1 exon 4 (1% ). In about 3% of cases, FLI1 exon 6 or exon 6 plus 7 are m issing from the gene fusion. T his variability has prom pted us to investigate a possib le prognostic im pact of the gene fusion type. (Zoubek et al., unpublished) . In addition, an independent Am erican study perform ed on a sim ilar sized cohort of patients after a m edian follow up of 31 m onths, using a sim ilar treatment regimen, not only supported our ® ndings but also identi® ed the EW S± ETS gene fusion type as a prognostic m arker independent from the presence of m etastases at diagnosis in a m ulti-variate analysis. 128 About 55% of the`non-type 1' group in the two studies w ere com prised of type 2 gene fusions. Because of the low incidence of the individual`other-gene' fusion types, no distinction has been m ade betw een various non-type 1 subgroups so far. In the absence of a biological explanation for the observed prognostic differences, large collaborative prospective studies are warranted to highlight the speci® c chim eric m olecules and the protein dom ains associated w ith adverse patients' outcom e. Still, about 20% of patients with localized tum ors and m ore than half of the patients with m etastases succum b from the disease despite the expression of a type 1 EW S± FLI1 gene fusion, suggesting the existence of additional adverse factors.
Com pariso n of pl6 gene status and clinical course of 23 EFT patients analyzed so far suggested an adverse prognosis asso ciated w ith this aberration independent from the extension of the disease. 113 T hese results, w hich have not been subjected to statistical analysis, m ust be considered as prelim inary since patients' num bers in the study were sm all and the median observation period did not exceed 2 years. Retrospective im m unohistochem ical analysis of biopsy m aterial from a large num ber of patients will help to clarify the prognostic relevance of a disrupted pRb cell cycle regulatory pathw ay in EFT . Also, m utation of p53 m ight be linked to an adverse outcom e, since none of the three EFT patients from our series carrying such an aberration survived. H ow ever, because of the rarity of this alteration it cannot serve as a useful prognostic m arker. A prognostic relevance for EFT of the observed num erical and structural cytogenetic changes has not been demonstrated with con® dence due to low sample num bers in the studies perform ed so far. M ost recently, deletion at 1p36, occurring in 6/22 localized EFT, was discussed as being asso ciated with unfavo rable outcom e in this group (Hattinger et al., unpublish ed).
In the absence of reliable m olecular m arkers to predict outcom e in EFT , the presence of clinically overt m etastases at diagnosis is com m only considered as the only prognostic criterion that is used for treatment strati® cation 
C onclusions
In this review, I have sum m arized evidence for the im portance of studying EFT-spe ci® c genetic alterations in an authentic cellular background. Since the histogenesis of EF T is still enigm atic and no experim ental evidence for E W S± FLI-m ediated tum origenesis has been reported from transgenic mouse m odels so far, EF T cell lines rem ain the only available system for such investigations. In this institution, cell lines could be established from 12 EFT patients with well docum ented clinical course. If a cell line could be expanded from the prim ary tumor, all subsequent tum or sam ples also gave rise to a cell line. All but one patient died from the disease suggesting that establishing a cell line selects for patients with adverse prognosis. In fact, 
